(function(){
			var content_array=["<p><b>关于<\/b><b>EFFISAYIL临床试验项目<\/b><\/p> \n<ul type=\"disc\"> \n <li>EFFISAYIL 1：使用佩索利单抗治疗GPP发作显示出快速的脓疱和皮损清除，疗效长达12周<sup>[12]<\/sup>。基于这一研究结果，佩索利单抗在包括美国、日本、中国大陆和欧盟等多个国家成为首个获批专门针对成人GPP发作的疗法<sup>[13],[14]<\/sup>。<\/li> \n <li>EFFISAYIL 2：一项多中心、随机、双盲、安慰剂对照的IIb期临床研究，评估将皮下（SC）注射佩索利单抗作为维持治疗，在青少年和成人中预防GPP发作和持续控制 GPP 症状的有效性和安全性<sup>[1],[2]<\/sup>。<\/li> \n <li>EFFISAYIL ON：评估佩索利单抗在参与过此前佩索利单抗临床试验的GPP患者中的长期安全性和有效性<sup>[15]<\/sup>。<\/li> \n<\/ul> \n<p><b>关于圣利卓<\/b><b><sup>&reg;<\/sup><\/b><\/p> \n<p>圣利卓（佩索利单抗）是一款新型人源化选择性抗体，可阻断白介素-36受体 (IL-36R)的激活。IL-36通路是免疫系统内的一种信号通路，已被证明与GPP等多种自身炎症性疾病的发病机制有关<sup>[5],[10],[16]<\/sup>。佩索利单抗已获得包括美国、日本、中国大陆和欧盟等多国监管机构批准，用于治疗成人GPP发作。<\/p> \n<p><b>关于泛发性脓疱型银屑病（<\/b><b>GPP）<\/b><\/p> \n<p>GPP是一种罕见的、异质性的、可危及生命的嗜中性粒细胞性皮肤病，临床上与斑块状银屑病不同<sup>[5]<\/sup><sup>,[<\/sup><sup>8]<\/sup>。GPP是由中性粒细胞（一种白细胞）在皮肤中积聚引起的，会在全身广泛爆发疼痛性的无菌性脓疱<sup>[5]<\/sup><sup>,[<\/sup><sup>8]<\/sup>。GPP患者的临床病程各不相同，有些患者可反复发作，而另一些患者则表现为疾病持续存在且间歇性发作<sup>[8]<\/sup>。虽然GPP发作的严重程度各不相同，但若不及时治疗，可能会出现败血症和多系统器官衰竭等并发症，可能会危及生命<sup>[5]<\/sup>。这种慢性全身性疾病会对患者的生活质量产生重大影响，并增加医疗负担<sup>[17]<\/sup>。GPP在不同区域的患病率各不相同，女性患者多于男性患者<sup>[5]<\/sup><sup>,[<\/sup><sup>17]<\/sup><sup>,[18],[19],[20]<\/sup>。对于能够快速解决GPP发作症状并能预防复发，且具有可接受的安全性的疗法存在着高度未满足的需求<sup>[4]<\/sup><sup>,[21]<\/sup>。<\/p> \n<p>GPP的发作可导致住院并可能发生严重并发症，包括心力衰竭、肾衰竭和败血症，而疾病发作的不可预测性和严重程度极大地影响了患者的生活质量<sup>[5]<\/sup><sup>,[<\/sup><sup>21]<\/sup>。<\/p> \n<div> \n <table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\"> \n  <tbody> \n   <tr> \n    <td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">[12] Bachelez H et al. Trial of spesolimab for generalized pustular psoriasis. NEJM. 2021;385:2431-40.<\/span><\/p> <\/td> \n   <\/tr> \n   <tr> \n    <td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">[13] Federal Drug Administration. New Drug Approvals for 2022. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761244s000lbl.pdf. Accessed January 2023.<\/span><\/p> <\/td> \n   <\/tr> \n   <tr> \n    <td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">[14] EC approval statement (data on file).<\/span><\/p> <\/td> \n   <\/tr> \n   <tr> \n    <td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">[15] Effisayil ON: An open-label, long term extension study to assess the safety and efficacy of spesolimab treatment in patients with generalized pustular psoriasis (GPP). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03886246?term=Effisayil&amp;draw=2&amp;rank=1. Last accessed January 2023.<\/span><\/p> <\/td> \n   <\/tr> \n   <tr> \n    <td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">[16] Furue K, et al. Highlighting Interleukin-36 Signalling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol. 2018;98:5–13<\/span><\/p> <\/td> \n   <\/tr> \n   <tr> \n    <td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">[17] Hanna M, et al. Economic burden of generalized pustular psoriasis and palmoplantar pustulosis in the United States. Curr Med Res Opin. 2021. 37(5):735-742.<\/span><\/p> <\/td> \n   <\/tr> \n   <tr> \n    <td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">[18] Augey F, et al. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur J Derm. 2006; 16(6):669-673.<\/span><\/p> <\/td> \n   <\/tr> \n   <tr> \n    <td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">[19] Ohkawara A et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background. Acta Derm Venereol. 1996 Jan;76(1):68–71.<\/span><\/p> <\/td> \n   <\/tr> \n   <tr> \n    <td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">[20] Jin H, et al. Clinical features and course of generalized pustular psoriasis in Korea. J Dermatol. 2015; 42(7):674-678.<\/span><\/p> <\/td> \n   <\/tr> \n   <tr> \n    <td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">[21] Puig L, Choon SE, Gottlieb AB, et al. Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals, and disease management. J Eur Acad Dermatol Venereol. 2023 Jan 6. doi: 10.1111\/jdv.18851.<\/span><\/p> <\/td> \n   <\/tr> \n  <\/tbody> \n <\/table> \n<\/div> \n<p>&nbsp;<\/p>"];
			$("#dvExtra").html(content_array[0]);})();